1.
Bull Exp Biol Med
; 145(3): 341-3, 2008 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19039939
RESUMO
Myelopid and MP-1 myelopeptide increase the count of antibody-producing cells, reduced under the effect of injury and standard therapy, and do not modify the suppression of delayed hypersensitivity. Injections of myelopid and MP-3 together with standard drugs optimized the traumatic inflammation processes.